New data analysis supports gocovri as an important treatment for motor complications for people with parkinson's disease

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, “effects of gocovri® (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with parkinson's disease and dyskinesia” in the peer-reviewed journal of neurology and therapy. th
ADMS Ratings Summary
ADMS Quant Ranking